HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Self-Regulation Group Sends Questions About PLx Pharma’s Vazalore Claims To FTC

Executive Summary

Over  past year, PLx's Vazalore ad claimswere reviewed National Advertising Division before and after launch. As PLx appeals NAD’s post-launch review findings, NAD attorneys send questions about pre-launch claims to FTC.

You may also be interested in...



PLx Will More Prominently Disclose ‘Clinically Shown’ Claim Refers To Vazalore 325-mg Aspirin

BBB National Programs’ appeals panel agrees with National Advertising Division that PLx should modify TV ad to clearly and conspicuously disclose that “clinically shown to cause fewer ulcers than plain aspirin” refers to Vazalore 325 mg and not 81-mg dose.

PLx Pharma Irritated By Industry Self-Regulation Group’s Findings On Vazalore GI Comfort Claim

PLx disagrees with National Advertising Division’s recommendations following review on Bayer’s challenge of TV commercial and will appeal findings to National Advertising Review Board. NAD attorneys thank PLx’s “ voluntary participation” in SWIFT review but PLx makes clear it didn’t agree to a SWIFT process.

Safe Use Of Hydrogen-Peroxide Contact Lens Solution Magnified in US FDA Draft Guidance

Draft guidance pulls from Ophthalmic Devices Panel and Risk Communication Advisory Committee 2017 meeting to discuss more clearly communicating risks of the solutions to consumers while allowing products to remain available OTC.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel